Systemic inflammation induces transient or permanent dysfunction in the brain by exposing it to soluble inflammatory mediators. The receptor for advanced glycation endproducts (RAGE) binds to distinct ligands mediating and increasing inflammatory processes. In this study we used an LPS-induced systemic inflammation model in rats to investigate the effect of blocking RAGE in serum, liver, cerebrospinal fluid (CSF) and brain (striatum, prefrontal cortex, ventral tegmental area and substantia nigra). Intraperitoneal injection of RAGE antibody (50 lg/kg) was followed after 1 h by a single LPS (5 mg/kg) intraperitoneal injection. Twenty-four hours later, tissues were isolated for analysis. RAGE antibody reduced LPSinduced inflammatory effects in both serum and liver; the levels of proinflammatory cytokines (TNF-a, IL-1b) were decreased and the phosphorylation/activation of RAGE downstream targets (ERK1/2, IjB and p65) in liver were significantly attenuated. RAGE antibody prevented LPS-induced effects on TNFa and IL-1b in CSF. In striatum, RAGE antibody inhibited increases in IL-1b, Iba-1, GFAP, phospho-ERK1/2 and phospho-tau (ser202), as well as the decrease in synaptophysin levels. These effects were caused by systemic RAGE inhibition, as RAGE antibody did not cross the blood-brain barrier. RAGE antibody also prevented striatal lipoperoxidation and activation of mitochondrial complex II. In conclusion, blockade of RAGE is able to inhibit inflammatory responses induced by LPS in serum, liver, CSF and brain.
The importance of systemic inflammation as a causative factor to the development of brain functional impairment, cognitive decline and neurodegeneration has been recognized. Clinical and experimental data indicate that both chronic and acute systemic proinflammatory processes affect central nervous system (CNS) function, leading to either transient or permanent dysfunction (Cunningham and Hennessy, 2015) . Chronic medical conditions with activated proinflammatory signalling, such as diabetes, obesity and atherosclerosis, have been associated with increased incidence of Alzheimer's disease (AD) and dementia (Holt et al., 2009; Nguyen et al., 2014) . In systemic inflammation induced by sepsis delirium is a common CNS manifestation during the acute phases, while a significant number of patients on recovery develop long-term functional impairment of the brain similar to neurodegeneration associated with brain trauma (Pandharipande et al., 2013; Widmann and Heneka, 2014) .
The receptor for advanced glycation endproducts (RAGE) is a multi-ligand receptor associated with distinct cell responses depending on the tissue of origin and developmental stage. RAGE is known to interact with a variety of ligands that may be classified as danger-or pathogen-associated molecular pattern molecules (DAMPs and PAMPs), including the S100 family proteins, HMGB1, amyloid-b peptide (Ab), bacterial lipopolysaccharide (LPS) and several advanced glycation endproducts (AGEs), among others (Xie et al., 2013) . RAGE is present only in mammals, where it is constitutively expressed in lungs and endothelial cells, but it may be http://dx.doi.org/10.1016/j.bbi.2017.01.008 0889-1591/Ó 2017 Elsevier Inc. All rights reserved.
up-regulated in most other cell types by DAMPs and PAMPs that evoke proinflammatory signalling (Creagh-Brown et al., 2010) . In such situations, RAGE-activated signalling induces the transcription of proinflammatory cytokines and also enhances its own transcription, establishing a positive feedback axis of proinflammatory signalling (Lukic et al., 2008) . Since its activation enhances its own expression, RAGE exerts a key role in the sustained proinflammatory states that occur with chronic diseases. This role has been well documented in diabetes, atherosclerosis, cancer, autoimmune diseases and some neurodegenerative conditions (Guo et al., 2008; Maczurek et al., 2008; Martens et al., 2012; Sims et al., 2010) . Microglial RAGE activation by Ab is believed to sustain the proinflamma tory/neurodegenerative axis in AD (Yu and Ye, 2015) and RAGE activation in brain is associated to memory impairment (Mazarati et al., 2011) . RAGE is also suggested to play a central role in the development of diabetic neuropathy and other neurodegenerative comorbidities of diabetes (Juranek et al., 2015; Sugimoto et al., 2008) .
RAGE blocking, using antibodies against RAGE or soluble isoform (sRAGE) that sequesters circulating ligands, is protective against systemic proinflammatory insults induced by sepsis and LPS endotoxemia van Zoelen and van der Poll, 2008; Yamamoto et al., 2011) . Immune neutralization of RAGE has been successfully performed with polyclonal, monoclonal or FAb fragments in vivo and in vitro (Bro et al., 2008; Tekabe et al., 2015) . In rodents, systemic injection of polyclonal antibodies against RAGE has been applied to inhibit RAGE signalling and was demonstrated to inhibit acute liver injury and fibrosis in a rat bile duct ligation model (Xia et al., 2016) , and experimental endotoxaemic liver failure induced by galactosamine and LPS in mice (Kuhla et al., 2013) . Abdominal sepsis induced by Escherichia coli was also observed to be significantly attenuated by polyclonal anti-RAGE (van Zoelen et al., 2009) , and in situ studies demonstrated that it is possible to achieve specific blocking of RAGE using polyclonal antibodies (Marsche et al., 2007; Origlia et al., 2014) . RAGE inhibition has also been suggested to be a potential molecular mechanism to alleviate neuroinflammation and neurodegeneration in AD, Parkinson's disease (PD), Huntington's disease (HD) and other similar conditions (Kim et al., 2015; Maczurek et al., 2008; Ray et al., 2016; Teismann et al., 2012) .
In rodent models of systemic inflammation induced by LPS, neuroinflammation and neurodegeneration are observed in brain structures related to dopaminergic function (Bodea et al., 2014; Qin et al., 2013) . Proinflammatory cytokines produced peripherally, such as liver TNF-a, are involved in the genesis and progression of neurodegenerative processes observed several months after a single LPS injection (Qin et al., 2007) . Episodes of acute systemic inflammation seem to play a major role in brain disease pathogenesis. In the present work, we investigated the role of RAGE in the short-term (up to 24 h) in serum, liver and CSF and the neurotoxicity-related effects induced by acute systemic inflammation in prefrontal cortex, striatum, substantia nigra (SN) and ventral tegmental area (VTA). Intraperitoneal administration of anti-RAGE IgG (RAGE-Ab) prior to LPS inhibited changes in proinflammatory, oxidative and neurotoxicity parameters that occurred in tissue specific manner 24 h after induction of systemic inflammation. All brain regions responded to LPS, but the striatum cytokine response was most susceptible to inhibition by RAGE-Ab. The present results suggest that RAGE exerts an important role in the propagation of acute systemic inflammation in the striatum within 24 h.
Materials and methods

Chemicals
Glycine, H 2 O 2 (hydrogen peroxide), thiobarbituric acid, bile salts and sodium dodecyl sulfate (SDS) were from Sigma-Aldrich 
Animals and drug treatments
Male Wistar rats (60-days old) were obtained from our breeding colony (n = 6 per group). They were caged in groups of four animals with free access (ad libitum) to water and standard commercial food (Chow Nuvilab CR-1 type; Curitiba, PR, Brazil). Rats were maintained in a twelve-hour light-dark cycle in a temperaturecontrolled colony room (21°C). Animals were handled for 7 days (adaptation period) to reduce stress caused by subsequent manipulation and weighting. After this adaptation period blood was sampled from the lateral tail vein (Lee and Goosens, 2015) . Rats were separated into four groups: a) control group -received one saline injection and one hour later a second saline injection; b) RAGE-Ab group -received one RAGE antibody (RAGE-Ab) injection and one hour later a saline injection; c) LPS group -received one saline injection and one hour later one LPS injection; d) RAGE-Ab+LPS group -received one RAGE-Ab injection and one hour later one LPS injection. In some experiments, isotype anti-rat IgG was used as control for specificity of RAGE-Ab.
All injections were administered i.p. The RAGE-Ab concentration (50 lg/kg) was selected based on previous reports (Kuhla et al., 2013; van Zoelen et al., 2009; Xia et al., 2016) and modified according our pilot experiments. We tested concentrations of RAGE-Ab up to 250 lg/kg and selected the lowest effective dose inhibiting liver ERK1/2 and serum TNF-a and IL-1b induced by systemic inflammation (unpublished data). The LPS dose of 5 mg/kg and via of administration (intraperitoneal) were applied based on results of previous works demonstrating acute changes in bloodbrain barrier (BBB) permeability followed by neurodegenerative progression over time using this procedure (Hoban et al., 2013; Qin et al., 2013 Qin et al., , 2007 , plus data from pilot experiments to assess mortality in the animals used in this study (Suppl. Fig. 1A and B). After 24 h, animals were anesthetized and the blood-free cerebrospinal fluid (CSF) was collected from the cisterna magna (Nirogi et al., 2009 ). An average volume of 100 lL of blood traces-free CSF per animal was obtained. Animals were euthanized by decapitation. The liver, serum, and brain structures (prefrontal cortex, striatum, SN and VTA) were isolated for analyses (see Fig. 1 ). Serum was separated from whole blood and used for ELISA as described below. Liver and brain were removed and the brain was quickly dissected using a rat brain matrix slicer and promptly homogenized. Tissue aliquots were homogenized in separate buffers according the respective procedure to follow, as described separately below. For brain immunofluorescence, animals were subjected to a different protocol of tissue preparation and isolation (see details below). To evaluate RAGE-Ab translocation through BBB, RAGE-Ab was conjugated to Alexa-Fluor 555 dye according kit's manufacturer instructions (Thermo Fisher, A20187) prior to i.p. injection procedure described above. In these animals, collected CSF was used to determine fluorescence intensity corresponding to Alexa-Fluor 555-conjugated RAGE-Ab. Alexa-Fluor 555-conjugated anti-rat IgG was used as control for RAGE-Ab. Repeated experiments with different animals were independently performed to obtain samples for multiple assays when required; the number of animals in each group (6) was always maintained.
Ethics statement
All experimental procedures were performed in accordance with the guidelines of the National Institutes of Health (NIH, 1985) and the Brazilian Society for Neuroscience and Behavior recommendations for animal care. Our research protocol was approved by the Ethical Committee for Animal Experimentation of the Universidade Federal do Rio Grande do Sul-Brazil (CEUA-UFRGS) under the project number #27683.
In vivo Evans blue dye (EBD) injection and dye extraction
In order to determine the effect of LPS on BBB permeability an EBD perfusion assay was performed as previously described (DalPizzol et al., 2013) . Injection of EBD is peripheral and its detection in brain is associated to BBB disruption, due to its high molecular weight (around 960 kDa). Twenty-four hours after LPS administration, the lateral tail vein was cannulated. EBD (4% solution in 0.9% saline), was injected as a single bolus dose of 2 mL/kg via cannula. After 120 min to enable uniform blood distribution, each rat was anaesthetized and thoroughly perfused with 0.9% saline to rid circulation of remaining dye, and the perfused brain was collected. For extraction, the right and left sides of each striatum were placed in 50% trichloroacetic acid (TCA), at a ratio of 30-35 mg striatum to 200 lL, and then homogenized for 5 min. The TCA brain extracts were centrifuged at 10,000g for 20 min to remove debris. The supernatants were added to a 96-well plate (30 lL per well, each plate supplemented with 90 mL of 95% ethanol and thoroughly mixed by pipetting) for detection of EBD emission of fluorescence in a microplate reader (620 nm/680 nm) (Wang and Lai, 2014) . The intensity of the EBD fluorescence leaking into the striatum provided an indication of the increased permeability of the BBB.
2.5. Enzyme-linked immunosorbent assay (ELISA) determination of cytokines and oxidative damage TNF-a and IL-1b were quantified with commercial kits and 4-hydroxinonenal (4-HNE) and nitrotyrosine were assessed by indirect assay. Liver and brain tissues were homogenized in phosphate buffer 50 mM (KH 2 PO 4 and K 2 HPO 4 , pH 7.4) and protein content measured. Tissue homogenate samples (30 lg protein/well), CSF and blood serum samples (100 lL) were placed in ELISA plates.
For TNF-a, and IL-1b quantification, kit manufacturer protocol was followed. For indirect ELISA, samples were incubated for 24 h in plates, and then washed three times with Tween-Tris buffered saline (TTBS, 100 mM Tris -HCl, pH 7.5, containing 0.9% NaCl, and 0.1% Tween-20). Subsequently, 200 lL of primary antibody against 4-HNE or nitrotyrosine (1:1000) were added and incubation was carried for 24 h at 4°C. The plates were washed three times with TTBS and incubated with rabbit or mouse IgG peroxidase-linked secondary antibody (1:1000) for 2 h. After washing the plate three times with TTBS, 200 lL of substrate solution (TMB spectrophotometric ELISA detection kit) were added to each well and incubated for 15 min. The reaction was terminated with 50 lL/well of 12 M sulfuric acid stopping reagent and the plate read at 450 nm in a microplate. The results are expressed in percentage to control.
Measurement of total thiol content
For total reduced sulfhydryl (-SH) content measurement, samples were homogenized in phosphate buffer and protein content measured. A sample aliquot (50 lL making 50 lg protein/well) was diluted with 120 lL of 50 mM PBS at pH 7.4 (NaCl, Na 2 HPO 4 , KH 2 PO 4 ) and 30 lL of a buffer pH 8.5 (boric acid 100 mM and EDTA 0.2 mM) mixed with 10 lL of 5,5 0 -dithiobis (2-nitrobenzoic acid) 10 mM. The reaction was read in a spectrophotometer at 412 nm after 60 min of incubation at room temperature (Ellman, 1959) .
Mitochondrial respiratory chain complexes activities
Tissues were homogenized (1:10, w/v) with SETH buffer (250 mM sucrose, 2 mM EDTA, 10 mM Tris-HCl, 50 IU/ml heparin, pH 7.4). The homogenates were centrifuged at 800g for 10 min at 4°C and protein content measured. Samples (6 lg protein/lL in 500 lL) were submitted to three freeze-thaw cycles to fully expose the enzymes to substrates. Ten microliters of supernatant (60 lg protein) were applied per well to measure the activities of succi nate-2,6-dichloroindophenol (DCIP)-oxidoreductase (succinate dehydrogenase), succinate:cytochrome c oxidoreductase (complexes II:III), NADH dehydrogenase:cytochrome c oxidoreductase (complexes I:III) and cytochrome c oxidase (complex IV) were determined by spectrophotometry kinetic measurements according previously described (Fischer et al., 1985; Rustin et al., 1994; Schapira et al., 1990 ) with modifications (da Silva et al., 2002) . 
Antioxidant enzymes activities
Catalase (CAT, EC 1.11.1.6), superoxide dismutase (SOD, EC 1.15.1.1) and glutathione peroxidase (GPx, EC 1.11.1.9) activities were quantified in tissue samples previously homogenized in phosphate buffer (pH 7.4) and normalized to 1 lg protein/lL. CAT activity was evaluated by determining the rate of H 2 O 2 absorbance decrease at 240 nm (Aebi, 1984) . In brief, 5 lL of each sample were added per well and mixed with 195 lL of phosphate buffer 50 mM at pH 7.4 (Na 2 HPO 4 , KH 2 PO 4 ). Hydrogen peroxide 1 mM (5 lL) was added to start the reaction and kinetic was monitored in a spectrophotometer. The activity of SOD was measured by quantifying the inhibition of superoxide-dependent adrenaline autoxidation to adrenochrome, which was monitored at 480 nm for 10 min (32°C) in spectrophotometer (Misra and Fridovich, 1972) . In brief, 5 ll of catalase (10 lM) were added in each well, followed by 10 lL of sample and 180 lL of glycine buffer (50 mM, pH 10.2). Epinephrine (60 mM, 5 lL) was added to start reaction. To determine GPx activity, the rate of NADPH oxidation was measured in the presence of reduced glutathione (GSH), tertbutyl hydroperoxide, and glutathione reductase as previously described (Flohe and Gunzler, 1984) . Ten microliters of sample were added per well, followed by 20 lL of NADPH (5 mM) and 170 lL of phosphate buffer (Na 2 HPO 4 , KH 2 PO 4 -20 mM, pH 7.7). The microplate was incubated during 10 min in 37°C then 10 lL of glutathione reductase (40 U/mL) + 10 lL glutathione (40 mM) + 20 lL of tert-butyl hydroperoxide (1 lL/mL) were added in each well. The reaction was monitored in spectrophotometer at 340 nm during 6 min.
Lipid peroxidation
The quantification of thiobarbituric acid reactive substances (TBARS) was performed for lipoperoxidation evaluation, as previously described (Draper and Hadley, 1990) . Liver and striatum were homogenized in phosphate buffer (pH 7.4) and protein content normalized for 1 mg/mL. Samples were mixed with 0.6 mL of 10% TCA and centrifuged (10,000g for 10 min). Supernatant was mixed with 0.5 mL of 0.67% thiobarbituric acid and heated in boiling water for 25 min. TBARS were determined by the absorbance in a spectrophotometer at 532 nm. Results were expressed as nmol TBARS/mg protein.
Total reactive antioxidant potential (TRAP assay)
The total reactive antioxidant potential (TRAP) assay was applied to assess the non-enzymatic antioxidant capacity of samples. This assay is based on the quenching of peroxyl radicals generated by addition of AAPH to samples (Lissi et al., 1992) and was performed as optimized by (Dresch et al., 2009) . In brief, samples were homogenized in phosphate-buffered saline and protein content normalized to 1 lg/lL in glycine buffer (100 mM, pH 8.6).
Supernatant is isolated and used for TRAP measurement. In separate vials, a chemical system that generates peroxyl radicals at a constant rate (AAPH 10 mM dissolved in glycine buffer, 4 mL) is coupled to a luminescent reactant (luminol 4 mM, 10 lL) which emits photons in proportion to its oxidation. The addition of the homogenate samples either decreases or facilitates the luminescence emission in proportion to its content of non-enzymatic antioxidants. The luminescence emission was recorded in a MicroBeta Ò luminescence counter (Perkin Elmer, USA).
Western blotting
To perform immunoblot experiments, the tissues were prepared using an radioimmunoprecipitation assay buffer protocol (Gasparotto et al., 2015) . The proteins (30 lg/well) were electrophoresed by SDS-PAGE and electroblotted onto nitrocellulose membranes with trans-Blot Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, CA, USA). Protein loading and electroblotting efficiency were verified through Ponceau S staining, and the membranes were washed with TTBS. Membranes were incubated for 20 min at room temperature in SNAP i.d. 2.0 Protein Detection System (Merck Millipore, MA, USA) with each primary antibody (all antibodies incubated at 1:500 dilution) and subsequently washed with TTBS. anti-rabbit or mouse IgG peroxidase-linked secondary antibody was incubated for an additional 20 min in SNAP (1:5000 dilution) and washed again, and the immunoreactivity was detected by enhanced chemiluminescence using Supersignal West Pico Chemiluminescent kit. The chemiluminescence was captured with an ImageQuant LAS 4000 (GE Healthcare). Densitometric analysis of the images was performed using ImageJ software (ImageJ v1.49, National Institute of Health, USA). Blots were developed to be linear in the range used for densitometry. All results were expressed as a relative ratio to b-actin or total isoform of the protein.
Reporter gene (Luciferase) assay
RAW 264.7 macrophage cells (obtained in the Rio de Janeiro Cell Bank, RJ, Brazil) were plated in 96-well plates and after 24 h transfected with 100 ng of a vector containing a responsive element to NF-jB driving firefly luciferease (pGL4.32 Luc2P-NF-jB Ò Promega) and 10 ng constitutive Renilla-luciferase construct (pRL-TK Ò Promega) per well. The transfection was carried by ViaFect Ò reagent (Promega) and Opti-MEM. Cells were also transfected with GFP vector to monitor the efficiency of transfection, and an empty vector was used as negative control. When more than 60% of cells display green fluorescence, NF-jB-luciferase and Renilla transfected cells were treated. Cells were pre-treated with RAGE-Ab at 20 lg/ mL and treated with LPS 1 lg/mL for 1 h. At the end of treatments, the cells were lysed and luciferase activity was assessed using the Dual-Glo Ò Luciferase Assay System (Promega). Results are expressed in ratio Luciferase/Renilla luminescence relative to control groups.
Immunofluorescence
Rats were perfused via the vascular system with descendent aorta clamped. Sterile saline was administered during 10 min followed by 10 min with paraformaldehyde (PFA) solution 4% in PBS (7.4). The brains were then carefully extracted and maintained in PFA 4% for 24 h at 4°C, then placed in sucrose 15% for 24 h at 4°C and placed for 24 h at 4°C in sucrose 30%. Brains were slightly dried and frozen in -20°C. After 24 h the striatum was sectioned in slices of 15 lm on the coronal plane using a cryostat at -20°C (Jung Histoslide 2000R; Leica; Heidelberg, Germany). A total of 20-30 slices per rat containing the striatum were collected in PBS containing Triton x100 0.1% (PBS-0.1%). The free-floating sections were incubated with albumin 5% during 2 h to block nonspecific binding sites. The antibody was incubated during 48 h at 4°C. Antibody dilution and catalogue number: Iba-1 (1:500; 019-19741) is from Wako Chemicals USA, Inc. (VA, USA). GFAP (1:500; #3670) is from Cell Signalling. DAPI for nucleic acid staining (1:500; D9542) is from Sigma-Aldrich Ò (MO, USA). Antibodies were diluted in PBS containing bovine serum albumin (2%). After washing four times with PBS-0.1%, tissue sections were incubated with secondary antibody according to reactive species (anti-rabbit or mouse Alexa 488 or 555 from Cell Signalling Technology Ò ), all diluted 1:500 in PBS and BSA 2%. After 1 h at room temperature the slices were washed several times in PBS-0.1%, transferred to gelatinized slides, mounted with FluorSave TM (345789 -Merck Millipore; MA, USA) and covered with coverslips. The images were obtained with a
Microscopy EVOS
Ò FL Auto Imaging System (AMAFD1000 -Thermo Fisher Scientific; MA, USA).
Protein assay
Total protein was quantified by Bradford assay and used to normalize all data (Bradford, 1976) .
Statistical analysis
Statistical analysis was performed with GraphPad Prism version 5.04 (GraphPad Software Inc., San Diego, USA). Data were evaluated by one-way ANOVA analysis and followed by Tukey's Multiple Comparison post hoc test. Differences were considered significant when p < 0.05.
Results and discussion
Systemic LPS induces peripheral inflammation, oxidative stress and neuroinflammation, followed by progressive neurodegeneration over a period of ten months (Hoban et al., 2013; Qin et al., 2007) . This model has been used to investigate the role of inflammation in the onset of neurodegenerative processes in the brain, and also has been applied to induce Parkinsons's disease-and major depression-like changes (Duty and Jenner, 2011; O'Sullivan et al., 2009; Qin et al., 2013) , thus constituting a suitable model to investigate the role of RAGE in systemic inflammation-induced CNS damage. We first evaluated inflammatory markers in serum and determined the effects of pretreatment with anti-RAGE rabbit polyclonal IgG (RAGE-Ab). Previous works using polyclonal anti-RAGE for immune neutralization in rodents applied doses varying from 200 lg/kg to 1000 lg/kg and above (Kuhla et al., 2013; van Zoelen et al., 2009; Xia et al., 2016) . Although unspecific binding of the blocking antibody was not reported in such studies, we tested a lower range of RAGE-Ab doses (from 50 up to 250 lg/kg) and selected the lowest concentration effective in inhibiting liver ERK1/2 phosphorylation induced by systemic inflammatory shock (unpublished data), as we wanted to avoid potential binding of RAGE-Ab to other proteins that could result from the use of higher doses.
LPS injection has been shown to initiate an inflammatory response that leads to the activation of macrophages, and other white blood cells (WBC). This in turn leads to the production of proinflammatory cytokines and a burst of NADPH oxidase activation with consequent generation of reactive species (Qin et al., 2013) . LPS (5 mg/kg) increased both serum TNF-a and serum IL1b 24 h after injection into rats ( Fig. 2A and B) . At 24 h, rats had lost approximately 10% of their body weight (Suppl. Fig. 1C ) and further increases in the dose of LPS (7.5 and 10 mg/kg) caused 100% of mortality 1 h after injection (Suppl. Fig. 1 A and B) . LPS (5 mg/kg) also increased serum 4-HNE and serum nitrotyrosine 24 h after injection ( Fig. 2C and D) and this is consistent with an oxidative stress response. Prior treatment with RAGE-Ab significantly reduced the production of the proinflammatory cytokines and serum 4-HNE and it reduced the mean level of serum nitrotyrosine ( Fig. 2A-D) . Overall these serum results indicate that LPS induces a substantial inflammatory response in rats and suggests that LPS also induces RAGE activation, which in turn facilitates many of these LPS induced inflammatory responses. Importantly, the use of a polyclonal isotype antibody not directed to RAGE (rabbit anti-rat IgG) was not able to produce an effect similar to RAGEAb over serum cytokines (Suppl. Fig. 1D and E) , confirming the specific activity of RAGE-Ab. Previous works observed that serum cytokines may present decreased levels compared to control 24 h after systemic injection with different doses of LPS (Fischer et al., 2015; Ong et al., 2016) . This is expected as the serum cytokine response to systemic LPS may vary according the dose and bacterial origin of LPS utilized. Systemic inflammatory response induced by LPS or pathogens is constituted by an acute proinflammatory activation followed by a counter-regulatory anti-inflammatory response, which may be even more harmful than the proinflammatory phase (Kumar et al., 2009; Van Amersfoort et al., 2003; Xu et al., 2012 ). In our model, serum cytokines at 24 h were still increased compared to control levels, but their levels were declining compared to 1 h after injection (Suppl. Fig. 1A and B) .
The increase in oxidative stress markers in serum is often associated to organ damage and release to the bloodstream. Previously, it was demonstrated that systemic injection of LPS to mice induced long-term neurodegeneration by a mechanism that was triggered by liver inflammation and secretion of TNF-a (Qin et al., 2007) . In order to thoroughly investigate the inflammatory effects of LPS and the mechanisms whereby RAGE activation facilitates many of these LPS induced responses we chose liver as our model tissue. This is because liver is one of the main tissue targets during systemic inflammation and it is a major source of systemic proinflammatory mediators, which when released can affect other organs, including the brain (Romero-Gomez et al., 2015) . The level of RAGE in liver was significantly increased by LPS 24 h after injection (Fig. 3A) . Prior treatment with RAGE-Ab decreased basal levels of liver RAGE and completely blocked the increase in RAGE induced by LPS confirming the utility of this approach. These results indicate that RAGE participates in maintenance of its own basal levels in liver during LPS induction of systemic inflammation. Classically, following ligand binding, RAGE activates NF-jB transcriptional activity and an increase in RAGE expression is induced, since the RAGE gene (AGER) possess a responsive element for NF-jB (Maczurek et al., 2008) . RAGE ligand binding increases RAGE availability, whereas RAGE inhibition decreases RAGE expression and protein levels. In this context, downregulation of RAGE expression generally evidences that RAGE signalling is inhibited, and these results indicate that the positive feedback axis of RAGE activation and up-regulation was successfully blocked.
Immune neutralization of RAGE with antibodies or FAb fragments has been extensively applied to inhibit RAGE, as a pharmacological inhibitor was not available until recently. Generally, the use of FAb fragments or monoclonal antibodies may present evident advantages compared to full-length polyclonal antibodies for this type of approach, as polyclonal antibodies recognize multiple epitopes and could potentially bind to other scavenger receptors that may share one or more epitopes. Besides, potential induction of receptor internalization could ''mask" the expected blockade of the receptor. Nonetheless, this blocking approach of RAGE using polyclonal antibody was previously applied in different rodent models of systemic inflammation, being demonstrated to successfully block RAGE activation and other proinflammatory effects related to RAGE signalling in similar conditions (Kuhla et . It is important to note, however, that LPS binds to multiple receptors (including RAGE) and trigger similar intracellular effects that are associated to proinflammatory activation, including NF-jB activation. In this context, the use of unspecific antibodies to neutralize RAGE could also inhibit other receptors, potentially Toll-like receptor 4 (TLR4), which is one of the main receptors to recognize and translate LPS proinflammatory signals. We tested the blocking effect of RAGE-Ab over NF-jB activation by LPS in a macrophage cell line through a luciferase-reporter transactivation assay and observed that RAGE-Ab significantly, but not completely, inhibited LPS-mediated NF-jB activity (Suppl. Fig. 1F ). This result is expected for macrophage cells that express both RAGE and TLR4 and are exposed to LPS, as selective blocking of RAGE would not inhibit TLR4-mediated NF-kB activation by LPS.
To further characterize the effect of RAGE blockade on LPS systemic inflammation, parameters related to LPS and RAGE signalling in liver were analyzed. The content of TLR4 was significantly increased by LPS in liver, and RAGE-Ab significantly, but not completely, inhibited this effect (Fig. 3B) . The Extracellular-signal Regulated Kinases 1 and 2 (ERK1/2) are intracellular downstream targets of both RAGE and TLR4. ERK1/2 are also activated in response to oxidative stress (Son et al., 2013) . Phosphorylated ERK1/2 levels were increased in the liver by LPS, and RAGE-Ab significantly, but not completely, inhibited this effect (Fig. 4C ). Overall these liver results indicate that RAGE signalling facilitates the upregulation of TLR4 and activation of ERK1/2 that occurs during systemic inflammation induced by LPS. Importantly, the use of a polyclonal isotype antibody not directed to RAGE was not able to produce a similar inhibitory effect over liver ERK1/2 phosphorylation by LPS, evidencing the specificity of RAGE blocking in this effect (Suppl. Fig. 1G ). Both RAGE and TLR4 trigger NF-jB activation during inflammatory stimulation. ERK1/2 are known to modulate the amplification of proinflammatory signalling resulting from RAGE and TLR4 ligand binding by causing NF-jB-dependent gene transcription activation (Mandrekar and Szabo, 2009; Ott et al., 2014) . NF-jB is a multi-subunit protein complex regulated by various mechanisms that affect interaction between the different subunits, which may culminate in translocation of the p50 and p65 transcriptional subunits to the nucleus. In unstimulated conditions, p50 and p65 subunits are sequestered in the cytosol in an inactive state by the inhibitory IjB subunits, which prevent nuclear translocation and consequent activation of gene transcription by p50/p65. Activation and modulation of NF-jB may occur through phosphorylation and/or ubiquitination of IjB subunits, which leads to dissociation from p50/p65 and proteosomic degradation; phosphorylation of p65 itself also positively modulates transcriptional activity (Viatour et al., 2005) . Systemic injection of LPS induced a significant increase in IjB phosphorylation, which was significantly, but not completely, inhibited in animals pretreated with RAGE-Ab (Fig. 3D ). This increase in phosphorylation was despite the total IjB level being significantly decreased in LPS-treated animals (Fig. 3E) . LPS also caused a significant increase in p65 phosphorylation, which was significantly, but not completely, inhibited in animals pre-treated with RAGE-Ab (Fig. 3F ). This increase in phosphorylation was despite the total p65 level being significantly decreased in LPS-treated animals (Fig 3G) . Overall these results suggest that, during systemic inflammation induced by LPS, activation of NF-jB through IjB and p65 regulatory mechanisms in liver results from multiple pathways, with RAGE participating in IjB and p65 phosphorylation and RAGEindependent pathways leading to IjB and p65 degradation.
LPS increased liver levels of TNF-a and IL-1b ( Fig. 4A and B ). Prior treatment with RAGE-Ab had no effect on the basal levels of these proinflammatory markers, but completely blocked the LPS induced increases in TNF-a and IL-1b. Overall these results indicate that RAGE activation significantly facilitates the effects of LPS on liver cytokine production. LPS increased liver levels of 4-HNE (marker for lipoperoxidation) and nitrotyrosine (marker of protein nitrosative damage) ( Fig. 4C and D) . Prior treatment with RAGE-Ab did not block the LPS induced increase in liver 4-HNE and only minimally reduced the mean level of liver nitrotyrosine. Damage to lipids is the main cause of cell rupture and release of many proteases and toxic substances, affecting other cells. We therefore also measured lipid damage in liver through the TBARS assay and observed that LPS increased TBARS, but this was also not reversed by RAGE-Ab (Fig. 4E) . Overall these results indicated that, unlike in serum, liver oxidative stress during acute systemic inflammation induced by LPS is not dependent on RAGE signalling. This suggested also that the liver is not the main source of 4-HNE and nitrotyrosine observed in serum, as RAGE-Ab blocked the increase in these markers in the circulation. It could also be possible that RAGE-Ab pre-treatment inhibited the release of these molecules from this tissue to the bloodstream, but this hypothesis should be examined in more details.
LPS has been used to induce neurodegeneration both by systemic or intracranial injection (Bodea et al., 2014; Qin et al., 2007) . In order to understand the role of RAGE in neuroinflammation triggered by systemic inflammation, we first evaluated parameters of proinflammatory activation in CSF, prefrontal cortex, striatum, SN and VTA. Systemic LPS administration increased TNF-a by 10-fold and IL-1b by 35-fold in CSF, and these effects were blocked in animals pre-treated with RAGE-Ab ( Fig. 5A and B) . Control experiments with anti-IgG isotype injection instead of RAGE-Ab failed to produce this inhibition, confirming the specificity of RAGE-Ab effect (Suppl. Fig. 1H and I ). As this effect was similar to what we observed in serum, it is possible that the increase in TNF-a and IL-1b in CSF is related to an influx of systemic cytokines via passage across the choroid plexus, or indirectly by passage across impaired blood-brain barrier (BBB) (Nirogi et al., 2009; Shen et al., 2004) . Cytokines can also be transported across the BBB by saturable transport systems, which are able to directly affect central nervous system functions (Liu and Bing, 2011) . We observed an increase in BBB permeability in animals subjected to systemic LPS injection by using the Evans blue translocation assay (Fig. 5C ), suggesting that this route was likely to have contributed to the CSF cytokine levels.
Local production of inflammatory cytokines by different brain structures were analyzed separately. TNF-a was not changed in any brain region after systemic LPS injection (Fig. 5D) , while IL1b was increased in striatum, prefrontal cortex and VTA (Fig. 5E) . The increase in IL-1b in the striatum was inhibited by pretreatment with RAGE-Ab, but there was no effect of RAGE-Ab on prefrontal cortex and VTA IL-1b levels. The fact that prefrontal cortex and VTA levels of IL-1b were not altered by RAGE-Ab, while the CSF levels were, suggests that IL-1b was produced locally in these regions. However, for the striatum which showed changes in BBB permeability, these results suggest that systemic inhibition of RAGE prior to LPS injection blocks either the local production of IL-1b in the striatum or migration of this cytokine into the striatum Fig. 5 . Effects of systemic administration of RAGE-Ab and LPS on brain cytokines and BBB permeability. Wistar rats received a single dose of RAGE-Ab (50 lg/kg i.p.) followed by a single dose of LPS (5 mg/kg i.p.); control group received saline. Twenty-four hours after LPS injection, CSF was obtained for determination of the content of A) TNF-a and B) IL-1b by ELISA. The brain of these rats was isolated for analysis of D) TNF-a and E) IL-1b in cortex, striatum, VTA and SN by ELISA. For C) Evans blue-based BBB permeability assay, rats were cannulated and perfused before brain extraction according description in ''material and methods" section. Evans blue-fluorescence in striatum was determined in control vs. LPS-treated animals. F) Passage of RAGE-Ab across the BBB was analyzed by evaluating the presence of RAGE-Ab conjugated with Alexa-fluor Ò fluorescent probe in CSF; conjugated anti-IgG was used for specificity control. Values represent mean ± SEM of samples obtained from six rats/group. One-way analysis of variance and Bonferroni Multiple Comparison post hoc test were applied for all data. The p values are embedded in figure. from the CSF. LPS was previously observed to alter Ab transport across BBB and this effect was not associated to BBB disruption, although it was not associated to changes in RAGE expression either (Jaeger et al., 2009) . In this context, it seemed important to determine whether systemically injected RAGE-Ab could translocate into the CNS in our model, in order to establish if any potential effects observed at CNS level could be ascribed to local RAGE blocking. We thus evaluated the translocation of RAGE-Ab across the BBB by pre-injecting animals with RAGE-Ab conjugated to a fluorescent probe (Alexa Fluor Ò ) and evaluating the presence of fluorescent probe in the CSF. Fluorescent conjugated RAGE-Ab is not detected in the CSF of animals treated with LPS, indicating that RAGE-Ab does not cross the BBB (Fig. 5F ). Using conjugated anti-rat IgG isotype as control, CSF fluorescence is significantly increased in animals treated with LPS. These results confirm that effects of systemic RAGE-Ab injection over the CNS are not due to RAGE inhibition in the brain, as RAGE-Ab did not have access to the CNS in our experimental conditions. Besides, this result suggests that RAGE-Ab prevents BBB disruption by LPS, since, opposite to RAGE-Ab, anti-rat IgG is detected in the CSF of LPS-treated animals.
The effects of systemic LPS and RAGE-Ab on the striatum were investigated further in order to determine which of the major cell types (microglia, astrocytes or neurons) were activated and what mechanisms were operating in this tissue. Unlike with the liver, there were no significant effects of systemic LPS on striatal RAGE levels 24 h after injection (Fig. 6A ) and RAGE-Ab did not significantly reduce basal RAGE levels in the striatum. This reinforces the hypothesis that effects of RAGE-Ab in the striatum were not due to local blocking of RAGE. Brain RAGE has been implicated in neurodegeneration in previous studies (Ray et al., 2016) , but these works examined much longer-term effects than 24 h. The microglial protein Iba-1, which is used as a marker of microglia activation, was increased in the striatum of animals subjected to systemic LPS and this increase was significantly inhibited by RAGE-Ab (Fig. 6B and G) . Microglia are key innate immune cells in brain homeostasis and are constantly scavenging the CNS for damaged or unnecessary neurons and infectious agents (Gehrmann et al., 1995) . The communication between peripheral inflammation and brain inflammation can result in the propagation of cytokines and chemokines within the brain by action of microglia (Chen et al., 2012; Norden et al., 2016) and microglia are known to be activated by systemic LPS (Qin et al., 2007) . Glial fibrillary acidic protein (GFAP) expression is increased in activated astrocytes during neuroinflammation and is considered to be a marker for astrogliosis (Niranjan et al., 2010) . Systemic LPS injection significantly increased GFAP levels in striatum, and this effect was completely blocked by RAGE-Ab ( Fig. 6C and H) . Finally, we compared the effect of RAGE-Ab with isotype anti-rat IgG over Iba-1 and GFAP immunolocalization to assess the inhibitory specificity of RAGE-Ab over microglia and astrocyte activation by LPS, which was confirmed as anti-IgG had no effect over LPS-induced Iba-1 and GFAP immunoreactivity ( Fig. 6G and H) .
The levels of synaptophysin, a protein marker of functional synapses in neurons (Tarsa and Goda, 2002) , was significantly decreased in LPS-treated animals (Fig. 6D) , suggesting that the activity of striatal neurons was markedly altered. Synaptophysin expression is changed in response to various stimuli that affect the architecture of neuronal interconnections where functional synapses are established. RAGE-Ab pre-treatment conserved the level of synaptophysin in LPS treated animals. RAGE activation in brain has been suggested to affect synaptophysin levels in response to Ab (Arancio et al., 2004) . Nonetheless, as our results indicate, the decrease in synaptophysin by LPS is very likely to be a consequence of systemic inflammation, as systemic RAGEAb rescued synaptophysin levels without crossing the BBB. In this context, it is possible that the action of RAGE over the modulation of peripheral proinflammatory mediators may be the cause, direct or not, of synaptophysin downregulation and consequent synaptic dysfunction in the striatum. Several studies have been indicating that neuroinflammation correlates with synaptic loss, and NMDA-related excitotoxicity in response to IL-1b, TNF-a, IL-6 and chemokines released by activated microglia and astrocytes during a major proinflammatory event. As our data indicated, systemic inflammation by LPS affected the BBB integrity, which allowed the passage of proinflammatory mediators to striatum and consequent glia activation. This has been proposed as a potential mechanism responsible by synaptophysin downregulation in major inflammatory insults (Rao et al., 2012) and our data suggests that systemic RAGE blocking probably prevented BBB integrity disruption by LPS and consequent microglia/astrocyte activation.
An increase in protein phosphorylation can indicate enzyme activation in cells due to increased protein kinase activity. Tau phosphorylation is increased in activated neurons as tau regulates neuron microtubule assembly and stabilization in response to phosphorylation by diverse serine/threonine kinases (Wang et al., 2012) . Hyperphosphorylated states of tau for extended periods are also associated with the formation of dense hydrophobic aggregates leading to neurofibrillary tangles, contributing to neurodegeneration in conditions known as tauopathies (Mazanetz and Fischer, 2007) . Tau phosphorylation at ser202 normally occurs during embryonic development, then ceases in the adult CNS; however, in AD, phosphorylation at this site is recapitulated and correlates with induction of abnormal phosphorylation states and neurofibrillary tangle formation (Goedert et al., 1998 (Goedert et al., , 1993 . Systemic LPS injection significantly increased tau ser202 phosphorylation levels in striatum after 24 h, and this effect was completely blocked by RAGE-Ab (Fig. 6E) . Total levels of tau did not present significant variations in relation to b-actin content (Suppl. Fig. 2F ). Although RAGE ligands have been previously observed to induce tau phosphorylation, the inhibitory effect of RAGE-Ab cannot be ascribed to RAGE blocking in striatum, as RAGE-Ab did not cross the BBB (Fig. 5F ). It is possible that, in response to systemic inflammation and BBB disruption induced by LPS, activated microglia and astrocytes release proinflammatory mediators that activate death receptors in neurons, which in turn activate ERK1/2, GSK-3b and CDK5-dependent tau phosphorylation, a classic neurotoxic cascade hypothesized for Alheizmer's disease (Zilka et al., Fig. 7 . Effects of systemic administration of RAGE-Ab and LPS on oxidative stress parameters and mitochondrial activity in striatum. Wistar rats received a single dose of RAGE-Ab (50 lg/kg i.p.) followed by a single dose of LPS (5 mg/kg i.p.); control group received saline. Twenty-four hours after LPS injection, striatum was isolated. A) 4-HNE (4-hydroxynonenal) and B) nitrotyrosine relative levels were analyzed by ELISA and C) lipoperoxidation was analyzed by TBARS determination. D) Mitochondrial complex I-III, E) complex II-Q (ubiquinone), F) succinate dehydrogenase G) complex II-III and H) complex IV activities were followed spectrophotometrically. Values represent mean ± SEM of samples obtained from six rats/group. The values are represented as percentage to control. One-way analysis of variance and Bonferroni Multiple Comparison post hoc test were applied for all data. The p values are embedded in figure. 2012). ERK1/2 phosphorylation was significantly increased by systemic injection of LPS and this effect was blocked by RAGE-Ab (Fig. 6F ). ERK1/2 are present in all three major cell types in the striatum and an increase in ERK1/2 phosphorylation is consistent with any or all of the three cell types being activated. Overall these results suggest that LPS activates microglia, astrocytes and neurons in the striatum 24 h after injection and RAGE-Ab significantly decreased this activation without affecting striatal RAGE levels. This, along with data from fig. 5F showing that RAGE-Ab does not translocate to the brain in LPS-treated animals, strongly suggests that systemic inhibition of RAGE activation can lead to blockade of the effects of LPS in the striatum. In a broader context, considering the effects of RAGE-Ab over parameters of inflammation and damage in all tissues analyzed, these results indicate that systemic blockade of RAGE protects the CSF and striatum by inhibiting the proinflammatory action of LPS at systemic level.
Oxidative stress is a major component in the neuronal death triggered by neuroinflammation during the progression of neurodegenerative conditions (Halliwell, 2006) . To further understand the importance of systemic RAGE blocking in the acute effects of systemic inflammation on striatum, we next analyzed oxidative stress markers and there were no alterations in 4-HNE and nitrotyrosine levels, two specific markers of oxidative and nitrosative damage to lipids and proteins, respectively ( Fig. 7A and B) . However, TBARS levels were increased in LPS-treated animals and systemic RAGE-Ab injection prevented this effect (Fig. 7C) . This result led us to analyze mitochondrial function by measuring the activity of the respiratory chain complexes in striatum, as mitochondrial activity is one of the main sources of reactive species production, along with NADPH oxidase, during an inflammatory burst (Halliwell and Gutteridge, 2007) . We observed that activities of complex II-ubiquinone, succinate dehydrogenase, complex II-III and complex IV were enhanced in LPS-treated animals. In liver LPS induced decreases in complex II activities while RAGE-Ab prevented this effect, no activities were found in other complex ( Fig. 7D-H) . We also analyzed parameters of antioxidant defence activation in striatum by assessing the activities of the enzymes CAT, SOD and GPx, the non-enzymatic antioxidant capacity by TRAP assay and quantification of total reduced thiol (sulfhydryl) groups. However, we did not observe any changes in these parameters (Supplementary Fig. 2A-E) .
Conclusion
Systemic inflammation induced by LPS has been applied in diverse protocols that affect the function of the nigrostriatal axis, resulting in deficits of motor function, dopamine loss and neurodegeneration (Byler et al., 2009; Qin et al., 2013 Qin et al., , 2007 . Here we applied a protocol of acute inflammation with a single LPS injection and examined short-term effects (at 24 h after LPS injection) in blood serum, liver, CSF, prefrontal cortex, striatum, SN and VTA. A summary diagram is provided indicating the major findings (Fig 8) . Inhibiting effects induced by LPS in liver and serum, RAGE-Ab prevented LPS-related effects in CSF and striatum, but not in prefrontal cortex, SN and VTA. Our hypothesis is that systemic RAGE-Ab administration prior to LPS injection blocks the effects caused by RAGE upregulation and activation in liver, thus preventing a cascade of proinflammatory events caused by RAGE at systemic level, which include the production and release of cytokines that reach the brain and affect the striatum in less than 24 h (Fig. 8 and graphical abstract) . Systemic RAGE activation contributes to BBB impairment and access of proinflammatory cytokines to the striatum, probably by stimulating the production and release of cytokines by liver. This is the first observation reporting the involvement of systemic RAGE signalling in neuroinflammation, tau phosphorylation, synaptophysin downregulation and brain redox impairment resulting from systemic inflammation. It remains to be determined, in the future, the role of RAGE in the long-term impairment of CNS functions that may evolve as consequence of systemic proinflammatory insults of different types. Also, it will be important to confirm if the involvement of RAGE in this process is restricted to CSF and striatum or if it affects other brain regions with time. In this context, evaluating neuroinflammation, oxidative stress, brain energy metabolism and parameters of neurodegeneration in longer periods after systemic LPS induction could be useful to determine the role of RAGE linking systemic and CNS inflammation. The mechanism by which RAGE exerts this role remains elusive ( Fig. 8 and graphical abstract) but our data suggest that inhibition of the RAGE pathway may be an effective approach to block proinflammatory insults affecting the CNS.
Acknowledgments
This work was supported by funds from the Brazilian research agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) #400437/2013-9, #443514/2014-3 and #401260/2014-3, Fundação de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS) #2299-2551/14-6, Propesq-UFRGS and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bbi.2017.01.008. Fig. 8 . Proposed mechanism of the role of RAGE on systemic inflammation and consequent BBB disruption, CSF proinflammatory cytokines and striatal damage 24 h after LPS induction. RAGE antibody pre-treatment prevents RAGE ligand binding and inhibits liver proinflammatory activation via NF-jB pathway. Increases in serum TNF-a, IL-1b and lipoperoxidation, as well as neuroinflammation and brain damage markers are all inhibited by systemic injection of RAGE-Ab.
